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Abstract
Background: Pityriasis rubra pilaris is a rare, chronic erythematous squamous disor-
der of unknown etiology. The disease is characterized initially by small follicular pa-
pules that coalesce into yellowish pink scaly plaques, palmoplantar keratoderma, dif-
fuse furfuraceous scale of the scalp, and frequent progression to exfoliative erythro-
derma. Generally it is difficult to discern pityriasis rubra pilaris from other skin con-
ditions but key-clinical features help in the diagnosis such as "islands" of spared skin
within generalized erythroderma, follicular keratotic plugs, and an orange hue of the
involved skin. Treatment options include topical vitamin D analogues, keratolytics,
systemic acitretin, methotrexate, cyclosporine, azathioprine, fumaric acid esters, pho-
totherapy, and anti-TNFα agents. Cases, of pityriasis rubra pilaris, successfully tre-
ated with a short-course ustekinumab therapy, have been reported.
Main observations:We report a 31-year-old man with pityriasis rubra pilaris, refrac-
tory to conventional treatments, successfully treated with ustekinumab monothera-
py for over 64 weeks.
After failing conventional systemic agents (cyclosporine, aciretin and methotrexate),
ustekinumab 45 mg has been prescribed, with the same dosing regimen as in psoriasis.
The patient improved dramatically within 4 weeks of the first injection, with marke-
dly less erythema and pruritus. Long-term control of the disease of the disease was
achieved (64 weeks of treatment).
Conclusion: We report this case in order to show the striking and rapid efficacy of
ustekinumab in reducing the signs and symptoms of the disease. Complete remis-
sion was achieved after the third injection, but also a long-term control of the dise-
ase. The therapy was well-tolerated in our patient and no adverse events occurred.
(J Dermatol Case Rep. 2013; 7(1): 5-9)
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Introduction
Pityriasis rubra pilaris (PRP) is an uncommon papulosqu-
amous keratotic dermatosis of unknown origin and consi-
derable clinical heterogeneity. The incidence is estimated
between 1: 5.000 and 1: 50.000 and equally affecting men
and women.1 It has a bimodal distribution of age onset con-
centrating in the first and fifth to sixth decades.
The pathogenesis has not been yet clarified but it is thought
to be the result of an abnormal immune response to some
antigenic stimuli including streptococcal infection.5
Griffiths2,3 divided PRP into 5 categories based on clinical
features, age of onset, and prognosis: classic adult type,
atypical adult type, classic juvenile type, circumscribed ju-
venile type, and atypical juvenile type. To these, an HIV-as-
sociated variant has been added to this classification sys-
tem.4 Table 1.
Classically PRP is characterized by small follicular papu-
les, scaly yellow-pink (salmon-colored) patches, and palmo-
plantar hyperkeratosis. Lesions are usually symmetrical and
diffuse, with areas of normal skin (islands of sparing). Pro-
gression to erythroderma is common as well as nail involvement
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Case Report
We report a 31-year-old man with severe PRP, refractory
to conventional topical and systemic therapies, since the
age of 18. Since 2010, the patient showed a progressive
erythroderma and cyclosporine has been prescribed at the
dosage of 5 mg/kg/day. After eight weeks the lesions pro-
gressed and the patient received acitretin (50 mg/day) for
3 months, without any improvement.
In January 2011 patient was referred to our Department
with a progressive hitching rash with erythema and scales
involving more than 80% of the body surface area (BSA) with
"islands" of spared skin. Palms and soles were hyperkerato-
tic. Nails showed thickening of the nail plate, subungual hy-
perkeratosis and longitudinal ridging (Fig. 1A,B,C). Also the
patient reported symptoms of pruritus.
The diagnosis of type I PRP was confirmed by histological
examination displaying irregular epidermal hyperplasia, with
alternating foci of parakeratosis and orthokeratosis in both
vertical and horizontal levels (the so-called "checkerboard
pattern") without neutrophils’ microabscesses, parakerato-
tic follicular lipping and a sparse infiltrate of lymphocytes
around dilated venules of the superficial plexus.
Clinical investigations and laboratory tests were perfor-
med in order to rule out the presence of systemic infections,
characterized by distal yellow-brown discoloration, subun-
gual hyperkeratosis, longitudinal ridging, nail plate thicke-
ning and splinter hemorrhages.
Pruritus may occur in the early stages of the disease. Pa-
tients may complain of pain and irritation in the mouth; mu-
cous membrane changes include a diffuse whitish appearan-
ce of the oral mucosa, lacy whitish plaques, grayish-white
papules and plaques, erythema, or possible erosions. Pa-
tients with extensive disease may develop ectropion, and
they have also reported blurred vision and dryness. Topical
therapeutic options include corticosteroids, vitamin D ana-
logues, and keratolytics, that are prescribed for mild and lo-
calized forms, while for severe forms of PRP, systemic reti-
noids (eg, acitretin) are used as first-line therapy, although
the results are variable.6
Other systemic agents such as methotrexate, cyclospori-
ne, azathioprine, fumaric acid esters, phototherapy,7-9 and,
most recently, biological agents, have been reported as ef-
fective in the treatment of PRP.
In literature, Tumor necrosis factor (TNF) blockers inclu-
ding etanercept, adalimumab, and infliximab showed to be
effective and they are currently available as a therapeutic
modality for PRP.10,11
Whereas, in the literature there are only two reported ca-
ses about the usage of ustekinumab in type I PRP.12,13
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Clinical Type Lesions’
distribution
Physical findings Natural course Percentage
Classical Adult Generalized
Onset is acute, and the features are
classic, including erythroderma with
islands of sparing, palmoplantar
keratoderma, and follicular hyperkeratosis
Remission in 3-4 y 55
Atypical Adult Generalized
Characterized by ichthyosiform lesions,
areas of eczematous change, alopecia Chronic intractable
5
Classic Juvenile Generalized
Very similar to type I; its onset is within
the first 2 years of life Remission in 1-2 y 10
Circumscribed
Juvenile Localized
It occurs in prepuberal children and is
characterized by sharply demarcated
areas of follicular hyperkeratosis and
erythema of the knees and the elbows
Unpredictable 25
Atypical Juvenile Generalized
It has an early onset and runs a chronic
course. It is characterized by prominent
follicular hyperkeratosis, sclerodermalike
changes on the palms and the soles,
and infrequent erythema
Chronic intractable 5
HIV-Associated Type
Face and upper
trunk Similar to type I, in HIV-positive patients Refractory
Increasing
Table 1. Types of pityriasis rubra pilaris.
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Figure 1
A,B,C: Rash with erythema and scales before treatment; D,E,F: Clinical improvement after first injection; G, H, I: Complete re-
mission after third injection; J, K, L: week 64 of ustekinumab treatment.
control of the disease (64 weeks of treatment). The therapy
was well-tolerated in our patient and no adverse events occurred.
In our experience, Ustekinumab is a tailor-made therapy,
especially comfortable for young people having (or running)
an active social and professional life (i.e. our patient is
freelance journalist).
Conclusion
PRP is an uncommon chronic or chronic relapsing inflam-
matory skin disease of juvenile or adult onset. The etiology
is unknown, and treatment is challenging as standard the-
rapies are lacking.
In our patient it is highly likely that ustekinumab was re-
sponsible for the clinical response. Failure of the cyclospo-
rine, acitretin and methotrexate therapies to control the di-
sease, and the rapid improvement related to the ustekinu-
mab administration, suggest an active role of the drug. The
patient experienced a significant improvement after the first
injection at week 4. In view of the response in the case de-
scribed here and the previous successful reports12,13 uste-
kinumab could be included as an alternative agent for tre-
ating adult-onset PRP. However, further studies are neces-
sary to more precisely evaluate its safety and efficacy.
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autoimmune diseases, comorbidity, and malignancies.
Based on the clinical and laboratory data, we prescribed
methotrexate 7,5 mg/week for 2 weeks, followed by metho-
trexate 10 mg/week and folic acid for another 4 weeks. Be-
cause of the ineffectiveness of methotrexate, we decided to
perform the mandatory panel of screening tests for biologi-
cal drugs, including chest X ray, ECG, and Quantiferon TB-Gold.
After obtaining the patient’s written consent and the ap-
proval of our local ethical committee, ustekinumab 45 mg
(patient’s weight = 80 kg) was administered subcutaneously
at week 0 and 4, and then quarterly, according to psoriasis
dose regimen.
Within the first 4 weeks of therapy, the patient markedly
showed an improvement of erythema, pruritus, and nail le-
sions. Overall, he showed a good improvement after the
first injection of ustekinumab (Fig. 1D,E,F).
Complete remission was achieved after the third injection
(Fig. 1G,H,I) and it was maintained for 64 weeks (Fig. 1 J,K,L),
with no adverse events reported. Currently, the patient con-
tinues ustekinumab treatment at the dosage of 45 mg eve-
ry 12 weeks, with a significant improvement in quality of life.
Discussion
The unclear pathogenesis of PRP is chiefly responsible for
the multiple and different treatments that have been used
for its management (including steroids, azathioprine, fuma-
ric esters, methotrexate, retinoids-currently deemed as the
first line treatment, cyclosporine, etc.).
Its low incidence hinders us from carrying out controlled
clinical trials, and so all the data available regarding thera-
py is based on case reports and small case series.11 Thera-
peutic approaches to the erythro-desquamative skin disor-
ders have significantly changed with the introduction of TNF-
alpha blockers and other biological therapies. As mentio-
ned, the use of infliximab, etanercept, and adalimumab, for
the treatment of PRP, in a monotherapy regimen, or com-
bined with methotrexate or acitretin is well documented,
with different degrees of success.
Ustekinumab is a fully human IgG1 K-kappa monoclonal
antibody, which suppresses both Th1 and Th17 pathways,
inhibiting the p40 subunit shared by interleukin (IL)-12 and
IL-23, that are crucial for T helper differentiation.
Ustekinumab is approved for the treatment of moderate-
to-severe psoriasis whereas, for PRP, its use is off-label.14
The information about the effect of ustekinumab on PRP
does not meet the requirements of evidence-based medicine.
In the case reported here, ustekinumab has been consi-
dered as the best therapeutic choice since it shows rapid ef-
ficacy, easy way of administration, with no hospitalization
and a prolonged time-gap between subsequent administra-
tions. Indeed, because of its 4-time subcutaneous admini-
stration per year, ustekinumab has low impact on patient’s
working and social life quality of life with a very high com-
pliance to treatment. Moreover, Ustekinumab demonstra-
ted a striking and rapid efficacy in reducing the signs and
symptoms of disease within 4 weeks of treatment and in in-
ducing complete remission after 28 weeks, and a long-term
Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris, Di Stefani et al.
J Dermatol Case Rep 2013 1, pp 5-9
8
13. Wohlrab J, Kreft B. Treatment of pityriasis rubra pilaris with
ustekinumab. Br J Dermatol. 2010; 163: 655-656. PMID:
20491761.
14. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C,
Wang Y, Li S, Dooley LT, Gordon KB, et al. Efficacy and safe-
ty of ustekinumab, a human interleukin-12/23 monoclonal
antibody, in patients with psoriasis: 76-week results from a
randomised, double-blind, placebo-controlled trial (PHO-
ENIX 1). Lancet. 2008; 371: 1665-1674. PMID: 18486739.
10. Ruzzetti M, Saraceno R, Carboni I, Papoutsaki M, Chimenti
S. Type III juvenile pityriasis rubra pilaris: a successful treat-
ment with infliximab. J Eur Acad Dermatol Venereol. 2008;
22: 117-118. PMID: 18181990.
11. Sehgal VN, Srivastava G, Verma P. Pityriasis rubra pilaris:
evolution of challenges in promising treatment options.
Skinmed. 2012; 10: 18-23. PMID: 22324172.
12. Ruiz Villaverde R, Sànchez Cano D. Successful treatment of
type I pityriasis rubra pilaris with ustekinumab therapy. Eur J
Dermatol. 2010; 20: 630-631. PMID: 20605773.
Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris, Di Stefani et al.
J Dermatol Case Rep 2013 1, pp 5-9
9
Note: Alessandro Di Stefani and Marco Galluzzo have equally contributed to this paper.
